Related Experiment Videos
Should ventricular premature depolarizations be treated? If so, how?
Insights
Complex ventricular premature depolarizations (VPDs) in ischemic heart disease increase sudden cardiac death risk. However, evidence is lacking to prove that reducing VPDs lowers mortality, necessitating careful clinical judgment for treatment decisions.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Complex ventricular premature depolarizations (VPDs) in ischemic heart disease, particularly with left ventricular dysfunction, correlate with higher sudden cardiac death rates.
- Current evidence from prospective, randomized, double-blind studies is insufficient to confirm that suppressing VPDs reduces mortality.
- Available antiarrhythmic drugs may be ineffective, potentially worsen arrhythmias, or cause toxicity, and spontaneous VPD variability can obscure drug efficacy.
Purpose of the Study:
- To review the current understanding of complex ventricular premature depolarizations (VPDs) in the context of ischemic heart disease.
- To discuss the challenges and considerations in managing VPDs, including drug selection, dosing, and monitoring.
- To outline criteria for initiating antiarrhythmic drug therapy in patients with VPDs and heart disease.
Main Methods:
- Review of existing literature on ventricular arrhythmias and sudden cardiac death in ischemic heart disease.
- Clinical experience and established guidelines for the management of ventricular premature depolarizations.
- Analysis of patient characteristics and risk factors associated with complex VPDs.
Main Results:
- No definitive data from randomized trials support mortality reduction by abolishing VPDs.
- Treatment decisions for VPDs require careful clinical judgment due to drug limitations and patient variability.
- Specific patient subgroups with complex VPDs and heart disease are identified as candidates for antiarrhythmic therapy.
Conclusions:
- The management of complex VPDs in ischemic heart disease necessitates individualized treatment strategies.
- Clinical assessment of risk factors, symptoms, and arrhythmia complexity is crucial for guiding therapy.
- Further research is needed to establish clear evidence-based guidelines for antiarrhythmic drug use in this population.
Abstract:
Complex ventricular premature depolarizations (VPDs) in the presence of ischemic heart disease, especially in the presence of left ventricular dysfunction, are associated with an increased incidence of sudden cardiac death. However, we have no hard data from prospective, randomized, double-blind studies demonstrating that abolition or reduction of VPDs will reduce mortality. Moreover, the drugs available to treat VPDs may not abolish or reduce VPDs in the individual patient, occasionally may exacerbate ventricular arrhythmias, and may produce toxic effects. Spontaneous variability of VPDs may also mimic an antiarrhythmic drug effect. Clinical judgment must be used to determine which patients with VPDs should be treated, with which antiarrhythmic drug or combination of drugs, given in what doses, to which blood levels or therapeutic endpoints. We need to determine in the individual patient which methods of monitoring the efficacy and toxicity of antiarrhythmic drugs should be used and how often. I treat patients with known heart disease with chronic oral antiarrhythmic drugs if they have frequent VPDs (more than five per minute), multifocal VPDs, couplets or short runs of ventricular tachycardia, or the R on T phenomenon. Patients with complex VPDs should especially be treated with antiarrhythmic drugs if they have survived a cardiac arrest, if they have poor left ventricular function, if they have sustained an acute myocardial infarction within 1 year, if they have unstable angina pectoris, if they have severe stable angina pectoris, if they have exhibited complex VPDs during treadmill stress testing associated with a low heart rate, an inappropriate blood pressure response to exercise, S-T segment depression at least 2.0 mm, or a short exercise duration, if they have a prolonged Q-Tc interval, and if they are symptomatic. I do not treat VPDs in asymptomatic patients who have no evidence of heart disease.